EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been recommended as the first-line treatment for advanced EGFR-mutant NSCLC patients (NSCLCm+)6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.